Fermenta Announces Granting of CEP by EDQM for VITADEE 100 SD, Enabling Accelerated Global Growth
THANE, India, July 30, 2025 /PRNewswire/ -- Fermenta Biotech Limited ("Fermenta"), a pioneer…
Ipsen announces changes to its Executive Committee
PARIS, FRANCE, 23 July 2025 - Ipsen (Euronext: IPN; ADR: IPSEY), a…
Essential Pharma appoints experienced pharmaceutical leaders Simon Ramsden and Rob Smith to leadership team
Essential Pharma appoints experienced pharmaceutical leaders Simon Ramsden and Rob Smith to…
Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology
Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease…
![Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]](https://i0.wp.com/ml-eu.globenewswire.com/media/NjEzMmQ4NzAtZTBkMS00ZDhhLTkyYjgtOGM3YzY1ZWM5M2U5LTEwMTQyODItMjAyNS0wNi0wMi1lbg==/tiny/Sandoz-International-GmbH.png?w=420&resize=420,280&ssl=1 "Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]")
Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1]
Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA…